MADRIGAL PHARMACEUTICALS INC (MDGL)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About MADRIGAL PHARMACEUTICALS INC
Madrigal Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on cardiovascular, metabolic, and liver disorders, with $958.4 million in revenue for FY2025. The company remains a clinical-stage biopharmaceutical business built around drug candidates for those disease areas and centered on therapies for metabolic and liver disease.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
MADRIGAL PHARMACEUTICALS INC's Technical Indicators Summary
MDGL is trading well above its key moving averages, including the 200‑day, which supports the overall buy stance while trend strength remains modest. Momentum readings are mixed — RSI sits in neutral territory and short momentum measures show some weakness — and MACD is flat, suggesting limited near‑term thrust. Volatility is moderate and consistent with the recent range, and on‑balance volume is positive, indicating institutional accumulation despite a shallow ADX that implies the uptrend is not yet forceful. Technical takeaway: Buy.
| Indicator | Value |
|---|---|
RSI (14) | 56.35 |
Stochastic %K (14, 3, 3) | 70.51 |
CCI (20) | 41.22 |
WPR (14) | -19.88 |
Momentum (10) | -4.39 |
MFI | 53.72 |
MACD Level (12, 26) | -1.19 |
Bollinger Bands | $476.68 - $575.48 |
ATR (14) | $23.30 (4.29%) |
ADX (14) | 18.02 |
OBV | 1,867,370 |
Classic Pivot Point | $527.88 |
Fibonacci Pivot Point | $527.88 |
Simple Moving Averages | $507.76 - $526.08(5 indicators) |
Exponential Moving Averages | $499.28 - $522.56(5 indicators) |
Get premium market insights delivered directly to your inbox.
Quote Summary
MDGL Headlines
Madrigal Pharma insiders cut stakes after earnings
March 7, 2026